Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-139

This is a really difficult one to value...

yes fast track is simply a designation given by the FDA (quite common), but I feel any news that shows progress with the COVID-19 ARDS trial and with the FDA will be magnified by the market... today's announcement is afterall the first public signal that the FDA is taking this trial seriously and has it on their radar... because there is so so much on the line here, and if you look at MSB's market cap right now... a positive trial read-out and/or EUA will see so much demand for this stock, especially from the US, we could easily see a market cap at 10x of where we are today.

For all the noise made on HC ... MSB is still very much an unknown and if the spotlight is shone on us in the coming months.. having Novartis as a partner will instantly give us market credibility and a reason to believe/jump on board very quickly IMO

Can't believe in the next few weeks.. we'll get two phase 3 trial read-outs (CHF is a larger market than all-cause ARDS, COVID-19 ARDS included)... and a 60% interim read-out.. main-event showing December 2020 on channel Mesoblast... let's hope it lives up to the expectation!

Goodluck all